MaaT013 is currently being investigated in a pivotal Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement. ARES is the first Phase 3 trial globally for a microbiome-based therapy in hematooncology. MicroiomePost discussed this topic with Savita Bernal, Chief Business Officer at MaaT Pharma, during the Microbiome Connect: USA 2022 congress, held last November in Boston.